Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormone Refractory Prostate Cancer Disease Clear all
Completed Phase 3 Interventional Results available

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

NCT00134056
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
atrasentan hydrochloride, docetaxel, prednisone, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
554
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

NCT02924766
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib, Apalutamide, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
West Hollywood, California • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 29, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
[Lu-177]-PNT2002, Abiraterone, Enzalutamide
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

NCT00585416
View directory record Official record
Conditions
Prostate Cancer
Interventions
CGC-11047
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

NCT02020135
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA ADC
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Tucson, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 29, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

NCT05501548
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer
Interventions
Olaparib, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005810
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, carboplatin, docetaxel, estramustine phosphate sodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

NCT07189403
View directory record Official record
Conditions
Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
DS9051b
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Sarasota, Florida • New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01881867
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 29, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

NCT03344211
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Radium Ra 223 Dichloride
Drug · Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

NCT00313781
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CP-751,871, docetaxel, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Pazopanib, Docetaxel, Prednisone Prostate

NCT01385228
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pazopanib, Docetaxel, Prednisone, Pegfilgrastim
Drug
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

NCT02130700
View directory record Official record
Conditions
Prostate Cancer
Interventions
VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

NCT00446836
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Paclitaxel polyglumex (Xyotax)
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 29, 2026, 5:36 AM EDT
Completed No phase listed Observational

Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

NCT02353715
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Abiraterone acetate, Sipuleucel-T
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 29, 2026, 5:36 AM EDT
Withdrawn Phase 2 Interventional

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

NCT01087580
View directory record Official record
Conditions
PROSTATE CANCER
Interventions
Docetaxel and Prednisone, Radiation Therapy
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 29, 2026, 5:36 AM EDT
Terminated No phase listed Observational

Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

NCT01076751
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06059118
View directory record Official record
Conditions
Prostate Cancer
Interventions
DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

NCT06966024
View directory record Official record
Conditions
Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Interventions
DCC-2812
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT07545811
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Interventions
JANX014
Biological
Lead sponsor
Janux Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
La Jolla, California • St Louis, Missouri • Charleston, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

NCT04737109
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer
Interventions
Ipatasertib, Darolutamide, Androgen Deprivation Therapy
Drug
Lead sponsor
David VanderWeele
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Indianapolis, Indiana • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 29, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

NCT03574571
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
40
States / cities
Gilbert, Arizona • New Haven, Connecticut • Newark, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

NCT05968599
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Enzalutamide, Abiraterone acetate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 29, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

NCT01511536
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel XRP6258, Abiraterone acetate, Prednisone 5 mg
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 29, 2026, 5:36 AM EDT